Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Autophagy Bladder Cancer

7 juli 2020 uppdaterad av: Shaimaa Ramadan, Assiut University

Identification of Novel Autophagy Markers in Bladder Cancer Patients

• Bladder cancer is the most common malignancy of the urinary tract. It represents the 7th most commonly diagnosed cancer in male population worldwide and drops to the 11th when both genders are considered . According to the American cancer society's estimates of bladder cancer in 2017, the number of the new cases of bladder cancer is 79,030, and the mortality figures reached 16,870 .

Studieöversikt

Status

Okänd

Betingelser

Blåscancer

Detaljerad beskrivning

In Egypt, Bladder Cancer is the most prevalent malignancy among Egyptian males (16%) producing more than 7900 deaths annually . The majority of patients with bladder cancer about (70-80%) present with non-muscle invasive bladder cancer .
Autophagy is a highly conserved catabolic process that degrades cellular organelles and proteins to maintain cellular biosynthesis during stress ; cancer cells induced autophagy to counteract with anticancer therapy by helping them to evade apoptotic pathway .Autophagy is achieved by many autophagy-related genes .
Previous studies found that human bladder cancer cell lines exhibit high basal level of autophagic activity that may contribute to resistance to current anticancer treatment, so targeting basal autophagy may help to develop novel therapeutic strategies . Autophagy is potently induced by activating transcription factor 6(Endoplasmic Reticulum stress marker) , and Malondialdehyde (oxidative stress marker) .
Recently several studies demonstrated the role of autophagy in Bladder Cancer progression as evidenced by detection of microtubule associated protein and its relevance with muscle invasion beside its grade dependency . Autophagy was grade dependent process . Autophagy related gene 7 is a key protein involved in autophagosomes biogenesis, Knockdown of Autophagy related gene 7 induced apoptotic cell death in bladder cancer cell lines measured by increased caspase 3 level, Based on these previous studies autophagy plays a role in bladder cancer progression so interruption of its pathway may serve a novel target for future therapies.

Studietyp

Observationell

Inskrivning (Förväntat)

150

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Egypten
- - Assiut, Egypten, 71111
    - assiut

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Barn
Vuxen
Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

patients with confirmed bladder cancer (histopathologically) having LGBC(Low Grade bladder cancer) undergoing either TUR(transurethral resection of Bladder Tumour) or Radical Cystectomy and patients having HGBC(High Grade bladder cancer) undergoing either TUR(transurethral resection of Bladder Tumour) or Radical cystectomy. Healthy controls[age and gender matched](with no previous history of gross hematuria, urolithiasis, or active urinary tract infection)

Beskrivning

Inclusion Criteria:

1)patients confirmed histopathologically to have bladder cancer. 2) Both sexes. 3) Patients who will accept to participate in the study.

Exclusion Criteria:

Patients with past history of Bladder Cancer with previous chemotherapy or any other types of cancer in the last 5 years.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Antal grupper/kohorter

Kohorter och interventioner

Grupp / Kohort
Low Grade group • 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy , The followings markers must be estimated : Autophagy markers: ( Atg7) level using (quantitative real time polymerase chain reaction). (LC3A)level using immunohistochemistry . ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay) Oxidative stress Marker:(MDA)using chemical method Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) .
High Grade group • 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy, The followings markers must be estimated : Autophagy markers: ( Atg7) level using (quantitative real time polymerase chain reaction). (LC3A)level using immunohistochemistry . ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay) Oxidative stress Marker:(MDA)using chemical method Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) .
Safety margin group • 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor), The followings markers must be estimated : Autophagy markers: ( Atg7) level using (quantitative real time polymerase chain reaction). (LC3A)level using immunohistochemistry . ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay) Oxidative stress Marker:(MDA)using chemical method Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).
Control group • 50 (age and sex matched )control The followings markers must be estimated : Autophagy markers: ( Atg7) level using (quantitative real time polymerase chain reaction). (LC3A)level using immunohistochemistry . ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay) Oxidative stress Marker:(MDA)using chemical method Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)..

Vad mäter studien?

Primära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
autophagy marker Tidsram: baseline	differences in the level of Atg7(autophagy marker) in Low Grade bladder cancer and High Grade bladder cancer groups in comparison with safety margin and healthy control group.	baseline

Sekundära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
stress markers Tidsram: baseline	Relation between LC3A and muscle invasiveness in bladder cancer progression, and relation between levels of ATF6, activating transcription factor6 (ER stress marker) -MDA malondialdehyde (oxidative stress marker)-Caspase3 (apoptotic marker) in different study groups and bladder cancer development.	baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Assiut University

Utredare

Huvudutredare: Shaimaa Shakhoun, assiut

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

1 december 2020

Primärt slutförande (Förväntat)

1 oktober 2021

Avslutad studie (Förväntat)

31 december 2021

Studieregistreringsdatum

Först inskickad

17 augusti 2017

Först inskickad som uppfyllde QC-kriterierna